In March 2013, we announced plans to establish a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. In February 2015, Cambridge City Council granted planning permission for our new site.
AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Address: da Vinci Building Melbourn Science Park Melbourn
Post Code: SG8 6EE
Country: United Kingdom
Website: http://www.astrazeneca.co.uk
Membership Type: Enhanced Founder
Our skills focus on the discovery, development and commercialisation of medicines for the treatment of some of the world’s greatest healthcare challenges. Our commitment to making a meaningful difference in healthcare is founded on the pursuit of scientific excellence that addresses unmet patient need. Science is at the heart of AstraZeneca’s future strategy and success – and our aspiration is to achieve scientific leadership.
In March 2013, we announced our UK global R&D centre and corporate headquarters will be based at the Cambridge Biomedical Campus. The new, purpose-built site will be home to around 2000 highly-skilled staff, as part of our plan to create strategic global R&D centres in Britain, the United States and Sweden. This will bring together our small molecule and biologics activity, creating opportunities to capitalise on the promise of small and large molecule combinations, improving pipeline productivity and establishing AstraZeneca as a global leader in biopharmaceutical innovation.
The Biomedical Campus will also become our largest centre for oncology research, as well as hosting our work on cardiovascular and metabolic diseases, respiratory, inflammatory, autoimmune and nervous system conditions. Projects here will also include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of pre-clinical research capabilities.
AstraZeneca has a long-standing presence in the UK and we're proud to be developing the next generation of medicines in Cambridge.
A global pharmaceutical company with a major UK presence. Through innovation and collaboration we can achieve better health for all.
St George Street Capital (SGSC), a UK registered charity, has signed a licence agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.
27-09-2019
Dr Jane Osbourn, Vice-President of Research and Development at AstraZeneca, has been made an Officer of the Order of the British Empire (OBE) in the Queen’s birthday honours list.
10-06-2019
AstraZeneca is hosting its second StartUP Science Competition for life science entrepreneurs in the Cambridge area.
08-05-2019
AstraZeneca and MSD Inc. have announced the European Commission has approved Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer.
12-04-2019
AstraZeneca's Forxiga is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes.
27-03-2019
AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the ESMO 2018 Congress (European Society for Medical Oncology) in Munich, Germany, 19-23 October.
11-10-2018
Are you an early-stage Cambridge start-up focused on life sciences/healthcare? Time is running out to enter AstraZeneca's first ever Start-Up Science competition for life science entrepreneurs in the Cambridge area.
25-05-2018
The Cambridge life sciences cluster has the potential to contribute an additional £1bn to the UK economy by 2032, according to independent research commissioned by AstraZeneca.
04-05-2018
AstraZeneca and Lucy Cavendish College, University of Cambridge, today announced that they have established a strategic collaboration to support their common goals of advancing women in science and business leadership, building on their existing relationship since the Company relocated its global HQ and R&D centre to Cambridge in 2016.
26-03-2018
At the American College of Cardiology (ACC) 67th Annual Scientific Session & Expo 2018 in Orlando, Florida, this weekend, AstraZeneca will deliver industry-leading science and insights that augment the body of evidence on clinical approaches to tackling cardiovascular diseases.
09-03-2018
AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio. The new company will focus on developing medicines for severe autoimmune diseases by targeting the underlying causes of each disease.
28-02-2018
AstraZeneca and MedImmune, its global biologics research and development arm, have been voted one of the top science employers worldwide, in the prestigious Science 2017 Top Employers Survey.
24-10-2017
An advanced cryo-electron microscope allows AstraZeneca and Laboratory for Molecular Biology (LMB) scientists in Cambridge to uncover ground-breaking insights into a prime therapeutic target in cancer.
23-05-2017
AstraZeneca has announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of...
04-05-2017
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab).
01-05-2017
AstraZeneca today announced that the European Commission (EC) has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
26-04-2017
Latest milestone since AstraZeneca moved its global HQ and strategic science hub to Cambridge, UK, where the company already has 2,000 employees
25-04-2017
AstraZeneca’s breast cancer treatment, Lynparza (olaparib), provided a statistically-significant improvement in progression-free survival compared to chemotherapy in the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.
17-02-2017
AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD). This agreement builds on the existing collaboration related to AZD3293, a BACE inhibitor in two pivotal Phase III trials.
04-01-2017
Repositive, a software company developing novel tools to improve discovery and access to human genomic research data, and AstraZeneca have announced the inaugural members of the PDX Consortium, which was set up to develop a collaborative, pre-competitive resource, to provide streamlined discovery and access to molecular data from Patient Derived Xenografts (PDXs) for use within oncology...
07-12-2016
Pages
Online at 10:00 - 11:30 (UTC+00:00) / 17:00 – 18:30 (UTC+08:00),
2 April 2020
Wuxi International Life Science Innovation Campus (I·Campus) has specially invited leading figures from life science industry, institutes, capitals and government sectors in both China and the UK to bring you an unmissable webinar. Different views from various perspectives will be shared on the evolving epidemic's macro-influence on the life science industry, companies' responding strategies, and new opportunities to arise in the post coronavirus era.
30/03/2020
Associate Director / Director, Statistical Innovation
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Cambridge
Salary Range:
30/03/2020
Director, Flu Manufacturing Science and Technology (MSAT),
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
GES Supplier Director
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Global Quality Business Process Owner (QC)
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Global Quality Lead – Lab Execution Systems & Pharmacopeia
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Graduate, Senior, Principal, Associate Director roles – Real World Evidence
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Cambridge
Salary Range:
30/03/2020
Medical Affairs Nominated Signatory , CVRM
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Medical Affairs Nominated Signatory , Respiratory
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Medical Head, ACT Program
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Cambridge
Salary Range:
30/03/2020
Patient Engagement Director - Respiratory
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Cambridge
Salary Range:
30/03/2020
Respiratory Safety Scientist - 12 Month Fixed Term Contract
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Senior Global Medical Affairs Leader, Rare Disease
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Cambridge
Salary Range:
30/03/2020
Senior Solution Architect - Manufacturing Execution Systems Infrastructure & Technology
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Senior/Principal Statistician, Statistical Innovation
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Cambridge
Salary Range:
30/03/2020
Shift Supervisor
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Supply Chain Process Specialist for Global External Sourcing
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Associate Director, Site Management and Monitoring, 12 months Fixed Term Opportunity / Secondment
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Associate Principal Scientist - Process Modelling
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
30/03/2020
Central Operations Leader
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Cambridge
Salary Range:
30/03/2020
Digital Procurement Strategy & Planning Manager
AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Location: Greater than 25 miles from Cambridge
Salary Range:
Pages
